<?xml version="1.0" encoding="UTF-8"?>
<p>However, there are competing ideas about the interference of JAK inhibitors with IFN-mediated antiviral activities. IFNs prohibit viral spreading in the early phase of infections. In animal models of SARS and Middle East respiratory syndrome (MERS), IFN-α and IFN-β showed benefit at the early stage but were harmful at the late phase. Patients with severe SARS who died of hypoxemia revealed high IFN-α, -γ, while those discharged from hospital had low IFN-α, -γ. Therefore, some experts suggested baricitinib’s use in the situation of hyperinflammation and cytokine syndrome, rather than in those with mild diseases.</p>
